Teva Canada Announces the Launch of a Generic Version of (PR)Abilify®, (PR)Teva-Aripiprazole Tablets for the treatment of Schizophrenia

- Currently Available in Canada -

TORONTO, Sept. 10, 2018 /CNW/ - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announces that the complete line of ^PrTeva-Aripiprazole (2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg tablets), a Health Canada approved, bioequivalent generic version of ^PrAbilify® (aripiprazole) is now available in Canada. This once-daily extended release prescription medication is indicated for the treatment of schizophrenia in adolescents 15-17 years of age and adults 18 years of age or older.

Teva-Aripiprazole (CNW Group/Teva Canada Limited)

"Each day, over 300,000ⁱ Canadians living with schizophrenia, their families and caregivers, deal with profound physical, emotional and financial tolls," said Christine Poulin, Senior Vice President and General Manager, Teva Canada. "The cost of their medication should not be part of the challenge. The launch of ^PrTeva-Aripiprazole provides patients with an affordable, bioequivalent alternative to ^PrAbilify® and demonstrates our ongoing commitment to improving people's lives."

Aripiprazole tablets (brand: ^PrAbilify®) had annual sales of approximately $182 million in Canada, based on IQVIA sales data as of July 2018. ^PrTeva-Aripiprazole is available immediately to pharmacies across Canada. This launch broadens Teva Canada's portfolio of medicines that treat mental health conditions to 28, including seven in the same therapeutic class as ^PrTeva-Aripiprazole (antipsychotic), all of which provide patients and payors with a full spectrum of affordable treatment options.

About Schizophrenia

Schizophrenia affects approximately 1% of the population in Canada or 1 in 100 persons. It is a severe mental disorder, characterized by profound disruptions in thinking, affecting language, perception, and the sense of self. It often includes psychotic experiences, such as hearing voices or delusions. It can impair functioning through the loss of an acquired capability to earn a livelihood, or the disruption of studies. Schizophrenia typically begins in late adolescence or early adulthood. Antipsychotic medication forms the cornerstone of treatment for schizophrenia.ⁱⁱ While there is no cure for schizophrenia, medication can reduce symptoms and significantly reduce relapses, and people affected by it can lead a productive life, integrated into society.ⁱⁱⁱ

Helping People Live Better Days

At Teva, we help to improve the health of 200 million people every day by providing innovative treatments and access to the world's largest medicine cabinet of generic and specialty medicines. This gives us a unique perspective on health. Understanding the many ways health impacts people's lives inspires us to discover new possibilities to bring medicines and more, enabling patients and caregivers to live better days.

About Teva Canada Limited

Teva Canada Limited, headquartered in Toronto, has provided affordable healthcare solutions for over 50 years, with sales of more than $1 billion in 2017 and over 249,000 prescriptions filled with our products every day^iv. Originally Novopharm Limited, Teva Canada Limited specializes in the development, production and marketing of high-quality generic prescription pharmaceuticals and through our branded division, Teva Canada Innovation, focuses on a diverse line of innovative products in a variety of therapeutic areas. Teva Canada employs more than 1,000 professionals, markets more than 400 products^v in 1,700 SKUs in Canada and is a subsidiary of Teva Pharmaceutical Industries Ltd., the world's largest generic drug maker. For more information, visit: www.tevacanada.com or www.tevamakesmedicines.ca.

About Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 45,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com.

__________________________________
i	Sources: Government of Canada, Public Health Agency of Canada Reports and Publications Archived: A Report on Mental Illnesses in Canada – Schizophrenia https://www.canada.ca/en/public-health/services/reports-publications/report-on-mental-illnesses-canada/schizophrenia.html | Statistics Canada, CANSIM, Table 051-0001 - Population as of July 1, 2017 | Population Estimates and Projections | Population by sex and age group http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo10a-eng.htm – Accessed September 2018
ii	Source: Government of Canada, Public Health Agency of Canada Reports and Publications Archived: A Report on Mental Illnesses in Canada – Schizophrenia https://www.canada.ca/en/public-health/services/reports-publications/report-on-mental-illnesses-canada/schizophrenia.html – Accessed September 2018
iii	Sources: American Psychiatric Association - What Is Schizophrenia? https://www.psychiatry.org/patients-families/schizophrenia/what-is-schizophrenia | Canadian Mental Health Association - Mental Health - Understanding Mental Illness - Schizophrenia https://cmha.ca/mental-health/understanding-mental-illness/schizophrenia | World Health Organization - What is schizophrenia? http://www.who.int/mental_health/management/schizophrenia/en/ – Accessed September 2018
iv	Source: IQVIA CDH & Compuscript MAT January 2018
v	Source: IQVIA CDH & Compuscript MAT January 2018

SOURCE Teva Canada Limited

IR Contacts United States: Kevin C. Mannix [phone]; IR Contacts Israel: Ran Meir [phone]; PR Contacts United States: Elizabeth DeLuca, [phone]; Israel: Yonatan Beker, 972 (54) 888 5898